PRT811, a protein arginine methyltransferase 5 (PRMT5) brain-penetrant inhibitor, has exhibited clinical activity and an acceptable safety profile in patients with IDH-positive recurrent, high-grade glioma and splicing mutation (SPLC)-positive uveal melanoma treated in the dose-expansion stage of a phase 1 study (NCT04089449), consistent with findings from the dose-escalation stage of the trial.
2023
KEYNOTE-716: Primary melanoma, not lymph nodes, should ‘drive therapeutic decision-making’
Three-year results show durable distant metastasis-free survival and RFS benefits with adjuvant pembrolizumab.
Biomarkers predict benefit of adjuvant nivolumab in resected melanoma
Four biomarkers appeared associated with longer RFS with nivolumab but not placebo.
Fianlimab/Cemiplimab Demonstrates Early Clinical Activity and Safety in Advanced Melanoma
The LAG-3 inhibitor fianlimab plus cemiplimab (Libtayo) produced high and consistent tumor responses and a comparable toxicity profile to that of anti–PD-L1 monotherapies in patients with advanced melanoma who were PD-L1 inhibitor–naïve in the advanced setting, according to data from a phase 1 study (NCT03005782) presented at the 2023 ASCO Annual Meeting.